Related Experiment Video
Updated: Jul 10, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
Published on: February 11, 2019
Discontinued drugs in 2006: central and peripheral nervous system drugs
1Neurology Centre of Excellence for Drug Discovery, GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, UK. Sue.D.Collins@gsk.co.uk
Abstract:
This perspective describes compounds that target the central and peripheral nervous system, whose development was discontinued in 2006 and which were being developed for the treatment of a range of neurological disorders, including chronic pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy and anxiety. These discontinued candidates are described by disease area, based on information available from the Pharmaprojects database.
Related Concept Videos
Centrally Acting Muscle Relaxants: Therapeutic Uses
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
Drugs Affecting Neurotransmitter Release or Uptake
Drugs Affecting Neurotransmitter Synthesis
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
CNS Depressants: Barbiturates and Benzodiazepines
Sedatives and Hypnotics Drugs: Barbiturates
